HDAC6 and Miyoshi myopathy: In 2018, the first HDAC6 degraders were developed by conjugating a pan-HDAC inhibitor with thalidomide analogs, leading to selective degradation of HDAC6 in MM.282 Various potent HDAC6 degraders were created by using the HDAC6-specific inhibitor nexturastat A, demonstrating promising anti-proliferation activity in MM cells.283,284 However, IKZF1/3 degradation was also observed in these studies.